✦ LIBER ✦

Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients

✍ Scribed by Mitsukuni Suenaga; Satoshi Matsusaka; Masashi Ueno; Noriko Yamamoto; Eiji Shinozaki; Nobuyuki Mizunuma; Toshiharu Yamaguchi; Kiyohiko Hatake

Book ID: 113049675
Publisher: Springer
Year: 2011
Tongue: English
Weight: 148 KB
Volume: 41
Category: Article
ISSN: 1436-2813
DOI: 10.1007/s00595-010-4432-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aflibercept plus FOLFIRI improves surviv

Aflibercept plus FOLFIRI improves survival in second-line treatment of metastatic colorectal cancer

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 220 KB

Phase II clinical trial of second-line F

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

✍ Horita, Yosuke; Yamada, Yasuhide; Kato, Ken; Hirashima, Yoshinori; Akiyoshi, Kou 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 334 KB

The Clinical Efficacy of FOLFIRI and Bev

The Clinical Efficacy of FOLFIRI and Bevacizumab in Combination as First-Line Therapy of Metastatic Colorectal Cancer

✍ Erin Grothey; Edward Chu 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow